DeepMed Research

LEO LABORATORIES LIMITED

🇮🇪Ireland

Country: 🇮🇪Ireland

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne

Phase 2

Completed

Conditions: Acne Vulgaris

Interventions: Drug: LEO43204
Drug: Placebo

First Posted Date: 2015-10-15

Last Posted Date: 2025-03-06

Lead Sponsor: LEO Pharma

Target Recruit Count: 59

Registration Number: NCT02575950

Locations: 🇺🇸
Torrance Clinical Research Institute Inc., Lomita, California, United States

LEO 124249 Ointment in the Treatment of Alopecia Areata

Phase 2

Completed

Conditions: Alopecia Areata

Interventions: Drug: LEO 124249
Other: Vehicle

First Posted Date: 2015-09-28

Last Posted Date: 2025-03-06

Lead Sponsor: LEO Pharma

Target Recruit Count: 40

Registration Number: NCT02561585

Locations: 🇺🇸
The Icahn School of Medicine, Mount Sinai Hospital, New York, New York, United States
🇺🇸
Northwestern University, Evanston, Illinois, United States

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

Phase 3

Completed

Conditions: Actinic Keratosis

Interventions: Drug: LEO 43204 gel
Drug: Vehicle gel

First Posted Date: 2015-09-15

Last Posted Date: 2025-03-10

Lead Sponsor: LEO Pharma

Target Recruit Count: 383

Registration Number: NCT02549339

Locations: 🇺🇸
Laser & Skin Surgery Center of Indiana, Carmel, Indiana, United States

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Phase 3

Completed

Conditions: Actinic Keratosis

Interventions: Drug: LEO43204 gel
Drug: Vehicle gel

First Posted Date: 2015-09-15

Last Posted Date: 2025-03-13

Lead Sponsor: LEO Pharma

Target Recruit Count: 391

Registration Number: NCT02549352

Locations: 🇩🇪
Klinik für Dermatologie & Allergologie Klinikum Vest GmbH, Recklinghausen, Germany

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

Phase 3

Completed

Conditions: Actinic Keratosis

Interventions: Drug: LEO 43204 gel
Drug: Vehicle gel

First Posted Date: 2015-09-11

Last Posted Date: 2025-03-10

Lead Sponsor: LEO Pharma

Target Recruit Count: 437

Registration Number: NCT02547233

Locations: 🇺🇸
Altman Dermatology Associates, Arlington Heights, Illinois, United States

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Phase 3

Completed

Conditions: Actinic Keratosis

Interventions: Drug: LEO 43204 gel
Drug: Vehicle gel

First Posted Date: 2015-09-11

Last Posted Date: 2025-03-10

Lead Sponsor: LEO Pharma

Target Recruit Count: 373

Registration Number: NCT02547363

Locations: 🇺🇸
Long Island Skin Cancer & Dermatologic Surgery, Smithtown, New York, United States

Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population

Phase 4

Completed

Conditions: Psoriasis Vulgaris

Interventions: Drug: Xamiol® gel
Drug: Daivonex® scalp solution

First Posted Date: 2015-08-27

Last Posted Date: 2025-02-24

Lead Sponsor: LEO Pharma

Target Recruit Count: 951

Registration Number: NCT02533973

Locations: 🇨🇳
The Second Affiliated hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris

Phase 2

Completed

Conditions: Skin and Connective Tissue Diseases

Interventions: Drug: LEO 90100 Aerosol foam
Drug: Betesil® 2.25 mg

First Posted Date: 2015-08-07

Last Posted Date: 2025-03-10

Lead Sponsor: LEO Pharma

Target Recruit Count: 35

Registration Number: NCT02518048

Locations: 🇫🇷
Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD), Nice, France

LEO 32731 - A Phase I Study in Healthy Subjects

Phase 1

Completed

Conditions: Psoriasis Vulgaris

Interventions: Drug: LEO32731
Other: Placebo

First Posted Date: 2015-08-04

Last Posted Date: 2017-05-03

Lead Sponsor: LEO Pharma

Target Recruit Count: 27

Registration Number: NCT02514694

Locations: 🇬🇧
Covance CRU, Leeds, United Kingdom

An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)

Phase 1

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: LEO 32731 cream
Drug: LEO 32731 cream vehicle

First Posted Date: 2015-07-14

Last Posted Date: 2017-05-03

Lead Sponsor: LEO Pharma

Target Recruit Count: 30

Registration Number: NCT02496546

Locations: 🇩🇪
Proinnovera GmbH, Center of Dermatology Excellence, Münster, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy